Agoracom Blog Home

Posts Tagged ‘CSE’

ImagineAR $IP.ca $IPNFF Announces That Major North American Sports & Entertainment Company Is Moving Forward With Augmented Reality Solution; Contract Is Imminent $SEV.ca $VST.ca $YDX.ca $NTAR.ca

Posted by AGORACOM-JC at 6:57 AM on Monday, July 27th, 2020
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg
  • Advises investors it has been put on notice by a major North American sports & entertainment company (“NASEC”) that a contract is imminent
  • Given the size of the NASEC and potential time necessary between our recent notification and actual completion of an agreement, ImagineAR felt this is sufficiently material news that warrants immediate disclose to our shareholders, even before the formal contract is awarded

VANCOUVER, BC and ERIE, Pa., July 27, 2020 – ImagineAR Inc. (CSE: IP) (OTC: IPNFF) (“ImagineAR” or “Company”) an Augmented Reality Company that enables sports teams, businesses, retailers and organizations to instantly create their own AR mobile campaigns, wishes to advise investors it has been put on notice by a major North American sports & entertainment company (“NASEC”) that a contract is imminent.

As with all large commercial contracts, the Company wants to clearly state there is a risk this deal may not close and cannot yet provide any assurances that it will close.  However, ImagineAR is of the opinion that all major hurdles have been dealt with and the path is now clear to contract. Given the size of the NASEC and potential time necessary between our recent notification and actual completion of an agreement, ImagineAR felt this is sufficiently material news that warrants immediate disclose to our shareholders, even before the formal contract is awarded.

Alen Paul Silverrstieen stated “We are taking the extraordinary step of advising our shareholders of an imminent material agreement with NASEC because we now expect it to be formalized in short order. I want to emphasize that no formal agreement has been executed and that we cannot provide any potential dates for or assurances of completion.”  

DISCUSSIONS WITH MAJOR BRANDS AND RETAILERS FOR AUGMENTED REALITY SOLUTIONS TO ENGAGE AND ACTIVATE CONSUMERS

ImagineAR is taking this opportunity to advise shareholders that we are in various stages of discussions with several major brands and retailers, which recognize the important role our Company’s augmented reality solution can play in delivering both consumer engagement and activation during this unprecedented time. Though none of these discussions have risen to the imminent status of NASEC, the Company can confirm that some are at advanced discussion stages.

IMAGINEAR JOINS GLOBAL SPORTS AND INNOVATION CENTER

ImagineAR has just joined the GSIC (Global Sports Innovation Center) powered by Microsoft with headquarters in Europe.  Earlier this month, ImagineAR was one of the 16 top-ranked start-ups of the 2020 WFS StartCup by GSIC World Football Summit and Global Sports Innovation Center and presented its fan engagement augmented reality platform to the judging panel.  Finalists are expected to be announced on July 27, 2020. 

The GSIC facilitates synergies and provides its partners with value-added services that enable sports entities and companies to grow and develop with the help of experienced professionals in different environments such as finance, innovation and product development.

This News Release is available on the company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About GSIC

Global Sports Innovation Center powered by Microsoft  (GSIC) is a business cluster powered by Microsoft Sport Team that gathers all kind of sports entities (clubs, federation, associations), institutions, tech-companies (from start-ups to enterprises), research organizations, investors and key figures of sport industry to improve its value chain. To do so we focus our activities and services on 6 main points: entrepreneurship, networking, applied research, showcase, Microsoft Partners Solutions and digital transformation advisory services. More than 340 companies from 38 different countries have already received support from the GSIC through different activities, as well as from their ambassadors and network of professionals of the sports industry.

More information at: http://sport-gsic.com/

About ImagineAR

ImagineAR Inc. (IP:CSE) (IPNFF:OTCQB) is an augmented reality (AR) platform, ImagineAR.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, (products, landmarks and more to instantly engage videos, information, advertisements, coupons,3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies. The AR Platform is available as an SDK Plug-in for existing mobile apps.

All trademarks of the property of respective owners.

ON BEHALF OF THE BOARD

Alen Paul Silverrstieen
President & CEO

(818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

Forward-Looking Statements/Information: 

This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond ImagineAR’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although ImagineAR believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, ImagineAR does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of ImagineAR should be considered highly speculative. There can be no assurance that ImagineAR will be able to achieve all or any of its proposed objectives. 

Neither the CSE Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE Exchange) accepts responsibility for the adequacy or accuracy of this release.

Essential Steps For Any Business To Prepare For Augmented Reality #AR SPONSOR: Imagine AR $IP.ca $IPNFF $SEV.ca $VST.ca $YDX.ca $NTAR.ca

Posted by AGORACOM-JC at 9:15 PM on Sunday, July 26th, 2020

SPONSOR: Imagine AR Inc. (IP:CSE) (IPNFF:OTCQB) is an Augmented Reality platform that allows businesses to easily launch AR campaigns. Clients Include: NBA Sacramento Kings, Mall of America, AT&T Shape and The Basketball Hall of Fame. The company recently announced partnership with Engaged Nation, an award winning leader in digital engagement marketing for casinos in addition to a collaboration with Music Superstar Flo Rida Learn More.

http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

Essential Steps For Any Business To Prepare For Augmented Reality

By: Michael Campbell Forbes Councils Member

EVP and General Manager of Augmented Reality at PTC, driving the commercial, product and technology strategy of the Vuforia business.

  • Augmented reality (AR) is a technology that transforms how information is captured, managed and communicated, both within a business and with its prospects and customers
  • It can significantly improve the way a business conducts collaborative engineering design reviews, sales and marketing, field service, skills transfer and manufacturing

However, AR’s transformative nature may make it hard to make decisions about. There is no real body of experience to refer to.

How can a business make itself ready to successfully apply AR? What will make implementation easier and more effective and ensure that the initial efforts provide a solid foundation for future transformation?

Knowing Where You Are And Where You Want To Go

There are two things you need to do at the very beginning: Identify a business goal, and assess what you are currently doing to achieve that goal.

A business goal can be retaining expertise by transferring skills from older or retiring workers to newer or unskilled workers. It can be providing product demos to prospects for products in a portfolio. It can be ensuring that engineers collaborate successfully on meeting permitting and safety requirements for new assembly lines across global locations.

Most importantly, what are the processes and procedures? Where are the bottlenecks or particular difficulties?

When considering where best to apply AR, further assessment is necessary — technology readiness. An impressive AR demo can be created for almost any business situation, but it’s important to choose a use case that can scale. AR can be used to improve routine, repetitive activities, but it won’t show its true value there, and investment in it will show less return.

AR really shines at helping with complex, varied and changing circumstances. The wider the range of product types, manufacturing procedures or workforce capabilities, the more clearly AR will show its value and the wider the organizational uptake will be.

Delivering AR To The User

AR content can be delivered to the end user in a variety of ways, and careful consideration of that user’s needs and the constraints of their work environment is necessary for a successful demonstration.

For example, a sales rep may need to present a broad portfolio of thousands of product configurations to prospects and customers. Currently, that may involve shipping samples to trade shows, providing spec sheets, and linking to diagrams and videos on webpages.

With AR, a customer can see all the details of a specific product, get a good idea of how it works and understand how it differs from the competition. Implementing AR on a phone or tablet can allow that sales rep to easily build a relationship with that customer, demonstrate a product of interest, communicate its details and use, and answer any technical questions while maintaining the touch essential to the sales process.

However, if the goal is to improve worker productivity on the production line, where various tools need to be picked up and used, AR content can be best delivered through a hands-free wearable, whether binocular eyewear such as Microsoft HoloLens or Magic Leap or monocular eyewear such as Google Glass Enterprise or the RealWear HMT-1. That information is overlaid on what the worker is seeing, whether it is instructions, fill levels or safety precautions, without interfering with the worker’s tasks.

It’s worth spending some time to really consider the various possible ways your AR could be used now and in the future so the chosen technology presents the information in an optimal way for the user.

Ensuring Access To The Necessary Content

An audit of the information necessary to build an AR experience that communicates effectively to the user can turn up gaps. This is fairly common because the range of information AR can communicate is much wider than is possible with existing channels. Ensuring the availability of this information as early in the process as possible can make for effective implementation.

If you want to provide procedural guidance to line workers, you must have — or be able to create or capture — digitized work instructions. If you want to provide 3D instructions on how to maintain and service a newly acquired machine, you must have the 3D CAD data. If you want workers to see diagnostic information about a machine’s performance such as vibration, temperatures and fill levels, that machine must have the necessary sensors and connectivity.

Identifying this information will require acquiring, storing, managing, distributing and analyzing new types of data and repurposing data you already have.

While not ideal, the lack of some information is not fatal. For example, if there is no 3D CAD data for your machine, using a head-mounted device to record an expert performing all the required maintenance procedures can fill the gap. However, identifying those gaps and planning methods for filling those gaps is essential.

Presenting That Content In A Useable Way

Technologies such as web and mobile apps, which were new not so long ago, are now established, and the methods for creating them and making them usable are defined. AR is much earlier in the process of becoming routine, so the specifics of AR usability still require attention.

Even an AR project that addresses a business goal, understands user needs and is supplied with the right content can fail if the user experience is inadequate. There are many ways to go wrong, from excessive or poorly organized information to inadequate visual contrast.

The need for usability is great, and tools to assist in AR content authoring are developing quickly. They’re already providing significant assistance to content developers, but understanding the capabilities and needs of the worker and rigorously establishing what information is most important in what context is key in this step.

You Are Ready For AR

Almost every business can improve efficiency, reduce costs, more quickly skill workers or ensure compliance through the information AR communicates. Choosing the right place to try AR first takes some thought and planning, which will enable an effective AR implementation that will provide a foundation for future growth.

Source: https://www.forbes.com/sites/forbestechcouncil/2020/07/23/essential-steps-for-any-business-to-prepare-for-augmented-reality/#67597b4c4550

Psychedelics Are Making a Wild Comeback – Let’s Not Eff It Up SPONSOR: MOTA Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 1:22 PM on Friday, July 24th, 2020

SPONSOR: Mota Ventures Corp is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business, Mota is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. Click Here for More Info

  • The consciousness-raising power of psychedelics are tripping up science once again – hopefully, we’re not headed for a refried version of legal weed

Timothy Leary must be rolling in his grave. Or maybe he’s just smiling to himself. We’d have to take a trip back in time to know for sure what the Harvard psychologist (and the granddaddy of the “psychedelic revolution”) would have to say about the “renaissance” in psychedelics we’re witnessing today, more than 50 years after he encouraged a whole generation to “turn on, tune in, drop out.” 

Johns Hopkins University, the U.S. Food and Drug Administration, research projects funded by billionaire tycoons and Silicon Valley bros micro-dosing magic mushrooms to boost productivity, the potential therapeutic benefits of psychedelics – psilocybin, LSD, MDMA and DMT (ayahuasca), you name it – are shaking up science again. 

The revolution Leary was talking about has seemingly returned full circle. These days you can’t go online without reading about another celebrity lending his name (it’s mostly men) to the promise of an exploding market in mind-altering drugs promising a cure for everything from depression to PTSD and addiction. Everyone seems to be looking for an angle on the next big thing. 

But like cannabis, psychedelics has its own dirty chapter steeped in the war on drugs. It’s a little known part of the counterculture revolution that seems another world away today. Indeed, psychedelics have long been thought of as something to be feared. 

Hopefully, we’re not headed for a refried version of legal weed where venture capitalists with listings on world stock exchanges are hell-bent on turning substances that could be the key to personal growth, into a commodity. 

That would be a shame because psychedelics not only have a proven track record in a myriad of therapies. They also have the power to make us more empathetic and deepen our understanding of ourselves and the world. To live, as Leary would say, on the astral plane.

If the pandemic has taught us anything it’s the importance of our connection to one another.

“People are feeling an increasing disconnection from themselves and from the world. The COVID crisis has exacerbated the situation, bringing issues around the meaning of life to the fore. How can we recover what’s known from the religious and wisdom traditions and mesh those with the best practices in cognitive psychology to achieve self-transcendence is part of a big revolution that’s happening in psychology and science right now. It’s starting to give us new ideas about practices and processes that we can align with psychedelic experiences. Do mystical experiences increase people’s sense of meaning in life? It seems like a fairly obvious question. But nobody was asking it. ”

John Vervaeke, assistant professor, Department of Psychology, University of Toronto.

War on psychedelics

It’s worth remembering in the current euphoria around psychedelics, that Leary went to jail (and often) for his LSD advocacy, at one point, labelled “the most dangerous man in America” by U.S. president Richard Nixon. 

Eventually, he would be sprung from a California prison by the Weather Underground – which was considered a domestic terrorism threat by the U.S. government – before ending up a fugitive from justice in Algeria and his eventual re-arrest in the United States some two decades later. 

Canada has its own history with psychedelics. And while it’s not as colourful as the U.S., the drugs are just as tightly regulated – if not more. 

There are efforts afoot to relax laws around psilocybin use. And a number of court challenges seeking the use of psychedelics for medical purposes. A grey market in psilocybin is also being allowed to thrive online. More Canadians are microdosing. (See article below).

But as with the first steps towards legal weed, the federal government seems intent on looking the other way – or leaving it up to the courts to decide.

The federal health minister, for example,  has the power to grant exemptions for the use of psychedelics in studies and has done so. 

But the government continues to refuse to grant exemptions for the use of psychedelics on compassionate grounds for individuals facing end-of-life illness.

There’s still huge stigma around psychedelics. And while the opioid crisis rages – another area where psychedelics have shown success as a treatment – the feds seem reluctant to act.

This week, BC Premier John Horgan wrote Prime Minister Justin Trudeau to formally ask that all drugs be decriminalized to “support people to access the services they need.” The Canadian Association of Chiefs of Police is also calling for the decriminalization of simple possession of illicit drugs without success. The group has also recommended the formation of a national task force to look into drug policy reform. This would seem like an opportune time.

“ There were more than 1,000 experiments that were published back in the 50s on the use of psychedelics. They were thought of as the hot new drug in psychiatry. Then the research stopped, it wasn’t necessarily because it was determined that the use of psychedelics was an unfruitful approach. It was more the political constraints. We’re seeing a rebound in these therapies because there is funding and more laxness around laws prohibiting research. But some of that may also have to do with the fact that, even though there are useful pharmacological interventions, they have serious limitations. The field of psychiatry has been in a bit of a frozen place where improvements in treatment for mental health have been quite minor and slow.”

Richard Zeifman, PhD student in clinical psychology, Ryerson University.

Fear of flying

While weed was saddled with the shame of reefer madness, psychedelics were drugs to be feared, liable to make you think you can fly, maybe even jump out a window. They were right about the flying part. 

The paradox is that psychedelics were being used successfully in psychology and psychiatry and to treat depression and alcoholism as far back as the 1950s. Their use was also leading to discoveries in the treatment of schizophrenia and suicidality. In fact, recent research shows that psychedelics suppress activity in the part of your brain responsible for fear.

The power of psychedelics to contribute to our personal growth, as Leary advocated, has been slower to take hold. That’s something for us hippies.

But cognitive scientists are again exploring how psychedelics can help “restore meaning and help us find wisdom in life,” says University of Toronto assistant psychology professor John Vervaeke.

The revival in psychedelics,” Vervaeke says, “is part of a larger set of issues that are happening in response to a crisis of meaning in society at large.

“There are all kinds of symptoms of this [crisis of meaning] – from the crisis in addiction to depression to increases in loneliness, suicide and the retreat of people into virtual worlds.” 

Psychedelics, says Vervaeke, “help block out the noise. Our relevance filter is not always tracking the truth properly.”

“ I hadn’t had any experience with psychedelics. Actually, I was very afraid of psychedelics which is interesting considering I was using a lot of very harmful street drugs. I was struggling for about 10 years with addiction and depression and anxiety. Then I heard about a clinical trial to treat addiction using psilocybin here in Vancouver. It was pretty serendipitous. I was feeling pretty desperate. I was willing to try anything. I found a lot of self-compassion and self-love using psilocybin. But I was still physically addicted to opioids. So that’s when we turned to Ibogaine, which really helped me with my detox. There was also a psycho-spiritual component. It’s really ineffable the experience you have on psychedelics. It was a very profound experience that allowed me to look at myself and the world very differently. My mindset completely changed. It helped me get through a lot of the mental illness I was struggling with on top of the addiction. It’s something I continue to do periodically. I don’t have to, but it’s something I choose to do because I find it meaningful and helpful on my path to recovery and personal development. It’s not a cure-all. It’s a tool. ” 

Adrianne, recovering opioid addict, subject of the documentary Dosed.

Spiritual mission

Ancient civilizations have known “the truth”  about the healing power of plant-based intoxicants for millennia. Native tribes of Mexico and the U.S. Southwest have been using peyote and psilocybin magic mushrooms in spiritual ceremonies since before first contact. For them, psychedelics were used as part of cleansing rituals, an idea Western culture looked down on or ignored.

When U.S. banker R. Gordon Wasson, the vice-president of J.P. Morgan & Company, became acquainted with shaman Maria Sabina and travelled to Oaxaca in 1956 to take part in a “holy communion” where “mushrooms were first adored and then consumed,” he wrote about it for Life Magazine. What he didn’t write about is that he took along a CIA agent for the ride. U.S. intelligence was apparently interested in developing a truth serum. They may have been onto something.

But Wasson’s hosts believed the mystical experiences brought on by the use of psychedelics (sometimes in heavy doses) led to transformational change in our perception of the universe that stayed with us long after the high faded. 

Clinical psychologists are discovering the same today. The effects of psychedelics like MDMA and psilocybin to treat PTSD can last for up to a year after just one therapy session, says Richard Zeifman, a PhD student in clinical psychology at Ryerson University, who has been tracking a number of research experiments in the area. 

We haven’t quite figured out the chemistry, but it has to do with psychedelics messing with the part of our brain repsonsible for fear.

“From a theoretical perspective, we know that some of the classic symptoms of PTSD are a tendency to want to avoid negative emotions or thoughts or memories related to a traumatic experience,” says Zeifman. “What MDMA and psilocybin do is create feelings of warmth and connectedness and reduce the extent to which people feel fear. It makes it tolerable enough for people to sit with their emotions.” 

“We have a medical focus with our dispensary. But the therapeutic aspects of psychedelics and the spiritual are intertwined. They are really part and parcel of the same thing – you don’t have to be sick to get a medical benefit. Experiments on psychedelics have been going on for decades. But its medicinal aspects are just starting to come above ground. We’re seeing a societal shift with psychedelics similar to cannabis. Where once cannabis users were looked upon as hedonists, we now understand that cannabis is useful medicine. We’re going to see the same thing with not only psilocybin, but LSD and MDMA as well. We’re already starting to see therapeutic safe spaces open up where people can take macro doses and have those experiences. There are incredible benefits to be gathered from this. They’re also easier to grow than cannabis. I suspect more Canadians are going to be growing their own mushrooms.”

Dana Larsen, founder, The Medicinal Mushroom Dispensary.

The Doors Of Perception

When English psychiatrist Humphry Osmond coined the term psychedelics at a 1957 meeting of the New York Academy of Sciences (from the Greek psyche, which means “mind,” and delos “to reveal,”), he was already successfully using LSD in the treatment of alcoholism and schizophrenia, including in one very well known study in Weyburn, Saskatchewan. 

By the time Aldous Huxley published The Doors Of Perception in 1950 on his experiment with mescaline, scientists were unlocking the secrets behind the hallucinogenic effects of psychedelics – and they were mind blowing.

Turns out the human body’s natural adrenaline also has a similar chemical composition to mescaline and shares some of the biochemistry of LSD.

“In other words,” Huxley wrote, “each one of us may be capable of manufacturing a chemical, minute doses of which are known to cause profound changes in consciousness.” 

The discovery gave rise to the notion that the human brain actually works as a “reducing valve” blocking out all but information that is practically useful to us. Psychedelics, the theory goes, act as a “bypass,” giving us the ability to think more clearly about things other than the junk of self-deception and ego that typically get in the way of the realizations of our true selves. Huxley referred to this state as the “Mind at Large” in which “is revealed the glory, the infinite value and meaningfulness of naked existence.” 

Psychedelics as a spiritual mission is an idea Huxley shared with Leary. The two would become founding members of the Harvard Psilocybin Project. The program conducted a number of experiments, including on reducing rates of recidivism among prison inmates. But its focus was more so on exploring and achieving a “profound religious state.” 

The project attracted widespread attention, including of the unwanted variety by government authorities. Soon LSD and psilocybin would be added to the Schedule 1 list of prohibited substances along with mescaline and peyote and the research into many promising fields would stop.

More than half a century later, psychedelics are experiencing a resurgence and being touted as part of a new “renaissance” in scientific research. Hopefully, we’re able to embrace the higher spiritual cause this time around.  

SOURCE: https://nowtoronto.com/news/psychedelics-drugs-mircrodosing-canada

$KABN.ca Liquid Avatar to Join Apex Comics Group Presentation at Comic-Con@Home $MOS.ca $MOGO.ca $CTZ.ca $PTO.ca $PAY.ca

Posted by AGORACOM-JC at 12:45 PM on Friday, July 24th, 2020
This image has an empty alt attribute; its file name is image-3.png

Good Afternoon,

We are pleased to announce that on Saturday, July 25 at 5 pm Pacific / 8 pm Eastern, in conjunction with Apex Comics group CEO and Founder, Mariano Nicieza, KABN will be presenting a virtual discussion and overview of the Liquid Avatar platform (www.liquidavatar.com) at Comic-Con @ Home for comic book, fantasy, anime, manga and gaming fans worldwide. The event can be viewed at: https://comiccon2020.sched.com/event/d4zK/apex-comics-publishing-group-2020-2021-exclusive-previews

For more information, please visit https://agoracom.com/ir/KABN

Thank you for your interest and support,

Kontrol Energy $KNR.ca Provides Update on Acquisition Closing Date $SNE $MSFT $HON $GOOGL $QCOM

Posted by AGORACOM-JC at 9:10 AM on Friday, July 24th, 2020
Kontrol Energy Corp. (@Kontrolenergy) | Twitter

TORONTO, ON / July 24, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol”) is updating its anticipated closing date for its previously announced acquisition (May 19th, 2020) (the “Acquisition“) of a building solutions company (the “Target“).

Subject to final Board approval, the Acquisition is scheduled to close on July 31st, 2020 (the “Closing Date”). This revised date was agreed on by Kontrol and the Target as it aligns with the Target’s fiscal year end of July 31st, 2020.

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Kontrol Energy is one of Canada’s fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean’s.


Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com.


For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward Looking Statements:

Certain information included in this press release, including information relating to future financial or operating performance and other statements that express the expectations of management or estimates of future performance constitute “forward-looking statements”. Such forward-looking statements include, without limitation, statements regarding the Acquisition and Closing Date, possible future acquisitions and/or investments in operating businesses and/or technologies, organic growth, the provision of solutions to customers and Greenhouse Gas emissions reductions, proposed financial savings and sustainable energy benefits and energy monitoring. Subsequent to year-end, there was a global outbreak of COVID-19 (coronavirus), which has had a significant impact on businesses through the restrictions put in place by the Canadian, provincial and municipal governments regarding travel, business operations and isolation/quarantine orders. At this time, it is unknown the extent of the impact the COVID-19 outbreak may have on Kontrol as this will depend on future developments that are highly uncertain and that cannot be predicted with confidence. These uncertainties arise from the inability to predict the ultimate geographic spread of the disease, and the duration of the outbreak, including the duration of travel restrictions, business closures or disruptions, and quarantine/isolation measures that are currently, or may be put, in place by Canada and other countries to fight the virus. Where Kontrol expresses or implies an expectation or belief as to future events or results, such expectation or belief are based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that the conditions to closing of the Acquisition will be satisfied, that financing will be completed, suitable businesses and technologies for acquisition and/or investment will be available, that such acquisitions and or investment transactions will be concluded, that sufficient capital will be available to Kontrol, that technology will be as effective as anticipated, that organic growth will occur, and others. However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, the conditions to closing of the Acquisition not being satisfied, lack of acquisition and investment opportunities or that such opportunities may not be concluded on reasonable terms, or at all, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected that customers and potential customers will not be as accepting of Kontrol’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise, except as required under applicable securities law.

SOURCE: Kontrol Energy Corp.

Else Nutrition $BABY.ca $BABYF Upgraded to OTCQX Best Market $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 8:56 AM on Friday, July 24th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Announced that its common shares have been approved for trading on the OTCQX® Best Market, a U.S. market operated by the OTC Markets Group
  • Else Nutrition’s shares were previously traded on the OTCQB® Venture Market
  • “We are very excited to have qualified to upgrade our US trading to the OTCQX Market,” commented Ms. Hamutal Yitzhak, Else Nutrition CEO and Co-Founder

VANCOUVER, BC, July 24, 2020 – Else Nutrition Holdings Inc. (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL) (“Else” or the “Company”), is pleased to announce that its common shares have been approved for trading on the OTCQX® Best Market, a U.S. market operated by the OTC Markets Group. Else Nutrition’s shares were previously traded on the OTCQB® Venture Market.

“We are very excited to have qualified to upgrade our US trading to the OTCQX Market,” commented Ms. Hamutal Yitzhak, Else Nutrition CEO and Co-Founder. “We believe that trading on the OTCQX Market will further raise visibility of Else Nutrition in the US and international marketplace as well as enhance trading liquidity and expand our shareholder base.”

The OTCQX Market is designed for established, investor-focused companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market from the OTCQB Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. and international investors.

The Company also announces that its board of directors has approved on the issuance of incentive stock options (collectively, the “Options”) to a number of its directors, officers, employees and consultants to purchase up to a total of 1,462,250 common shares in the capital of the Company (each, a “Common Share”). Of such Options, an aggregate of 687,500 Options are allocated to the directors and officers. This is a normal-course option grant that comprises part of the long-term compensation and retention incentives provided by the Company.

Each Option is exercisable into one Common Share up to five years from the issuing date at a price of CND $2.19 per Common Share or in the case of 72,000 Options to be granted to a certain consultant, at the closing price of the Common Shares on TSX Venture Exchange on the date immediately preceding the effective Option grant. The grant of the Options is subject to approval from the TSX Venture Exchange and the terms and conditions of the Company’s shareholder approved 2019 Stock Option Plan.Else Nutrition shares also trade on the TSX Venture Exchange under the symbol BABY and on the Frankfurt Stock Exchange under the symbol 0YL.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QB board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board  members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies,  and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among othersForward-looking statements made in this press release assume, among others, the timing of the Company’s toddler nutrition product launch and the availability of the Company’s product online. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements.  Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Avicanna $AVCN.ca announces the award of two Canadian government NSERC grants: 1) Cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 in collaboration with the University of Toronto; and, 2) Evaluation of cannabinoids for reversing cannabis-based toxicosis in collaboration with the University of Guelph $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 8:00 AM on Friday, July 24th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

In addition to a recent MITACS award, Dr. Christine Allen, a Professor at the University of Toronto, was awarded an NSERC Alliance grant for development of cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 induced lung inflammation

Avicanna further expands its existing neurobiological research collaboration with Dr. Jibran Khokhar, a Professor at the University of Guelph, with a 2-year NSERC Alliance grant to investigate the neural basis of cannabis-induced toxicosis

The two NSERC grants leverage the proven track record of Avicanna, the University of Toronto and the University of Guelph in the research and clinical development of cannabinoid-based medicines

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

TORONTO, July 24, 2020 – Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that the Company’s research collaborators have received two independent peer-reviewed grants from the Natural Sciences and Engineering Research Council of Canada (“NSERC“). The NSERC Alliance grants will be used to expand the investigators’ collaborative research with Avicanna.

For the past three years, Dr. Christine Allen’s research group (CARG) in the Leslie Dan Faculty of Pharmacy at the University of Toronto has supported the development and optimization of Avicanna’s cannabinoid-based products including commercial cosmetics (Pura H&W) and medical cannabis (Rho Phyto) product lines and the pharmaceutical pipeline that is currently under clinical investigation.  Dr. Allen will now leverage a recent MITACS award in addition to this NSERC Alliance grant in collaboration with Avicanna to develop a cannabinoid-based formulation for treatment of COVID-19 related lung inflammation.

A second NSERC Alliance grant was awarded to Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, who has an extensive track-record in behavioural pharmacology and neuroscience. Avicanna’s research program with Dr. Khokhar focuses on evaluating a variety of cannabinoids in several preclinical models of human psychiatric conditions including mental health disorders such as anxiety, depression, and PTSD. The NSERC grant was awarded to evaluate the neurobiological underpinnings of cannabis toxicosis in a preclinical model, and test the potential efficacy of Avicanna’s naturally-derived cannabinoids and formulations in the treatment of cannabis-induced toxicosis. With the recent changes in the Canadian regulations for Cannabis 2.0 allowing for cannabinoid edibles and vapes, there is concern around an increased risk for adverse events arising from accidental high-dose cannabis ingestion. Thus, this two-year project will determine the behavioural and neural correlations of cannabis-induced toxicosis and the effects of cannabinoids for counteracting cannabis-induced toxicosis.

Dr Jibran Khokhar, commented, “This research is extremely timely with the new Cannabis 2.0 regulations and the increased risk for cannabis-induced toxicosis. I am thankful to NSERC and Avicanna for support of this important research that will have an impact in our understanding of the neurobiological underpinnings of, and provide novel treatment avenues to treat, adverse events related to high-dose cannabis exposures.”

About Avicanna Inc.

Avicanna is an Ontario, Canada based corporation focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna’s two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna’s cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna’s research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna’s scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna’s research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics, and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the Company and CARG to develop cannabinoid-based pharmaceutical formulations to treat COVID-19 induced lung inflammation, the ability of the Company to develop cannabinoid-based pharmaceutical products, the results of the two-year project with the University of Guelph determining the behavioural and neural correlations of cannabis-induced toxicosis and the effect of cannabinoids to counteract cannabis-induced toxicosis. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE Avicanna Inc.

Empower Clinics $CBDT.ca Reports Fiscal 2019 Results $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:19 AM on Friday, July 24th, 2020

– 15,920 patient visits generating total revenue of $2,031,581 or $0.02 per share, compared to 7,607 patient visits generating $1,091,386 or $0.02 per share for fiscal 2018.

VANCOUVER, BC /July 24, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTC PINK:EPWCF)(Frankfurt:8EC)(“Empower” or the “Company“) has filed today its audited consolidated financial statements and related management’s discussion and analysis, both of which are available at www.SEDAR.com. All financial information in this press release is reported in United States dollars, unless otherwise indicated.

“2019 is defined by profound change for our Company setting the stage for the ongoing transition to a growth-oriented health & wellness brand, with substantially improved operating controls and improved cost structure.” said Steven McAuley, Chairman and CEO. “As we look ahead navigating a global pandemic, we find ourselves thriving, hiring and seeing patients in record numbers, further supporting our diversification to broader wellness services.”

2019 Highlights

  • 15,920 patient visits generating total revenue of $2,031,581 or $0.02 per share, compared to 7,607 patient visits generating $1,091,386 or $0.02 per share for fiscal 2018.
  • Net loss of $4,301,663 or $0.04 per share, compared to $3,789,918 or $0.06 per share for fiscal 2018, which was primarily driven by the recognition of goodwill and intangible asset impairment losses related to the Sun Valley acquisition which arose due to changes in Arizona licensing requirements.
  • Cash used in operating activities was $2,273,188 or $0.02 per share, compared to $2,835,711 or $0.04 per share for fiscal 2018.
  • Cash at December 31, 2019 of $179,153, compared to cash of $157,668 at December 31, 2018.

Recent Highlights Subsequent to Year End

  • Private Placement: April 2020 Empower Clinics closes private placement of $653,000 CAD to support growth initiatives.
  • Psychedelics Division: May 2020 Empower enters into a term sheet to acquire an interest in the global royalty rights of Dosed Movie, launches Dosed Wellness, a psychedelics brand, launches new dedicated website www.dosedwellness.com and adds new team members dedicated to the new brand.
  • COVID-19 Testing: April 2020 the Company launches a four-phase roll-out of COVID-19 testing in clinics and onsite for businesses.
  • Cannvas Education Platform: May 2020 Empower and EuroLife Brands complete definitive agreement for multi-year, multi-national licence of EurolIfe’s cannvas.me web-based education technology platform to deliver brand, product, and industry knowledge to the market.
  • Private Placement: July 2020 Empower Clinics closes private placement of $720,866 to support growth initiatives.

Financial Summary

Financial Performance

Clinic revenues for Q4 and full year 2019 were $542,677 and $1,949,549, respectively, compared to Q4 and full year 2018 revenues of $196,909 and $1,091,386, respectively. This increase above prior year is attributable to the acquisition of Sun Valley and the addition of 5 clinics which drove an increase in patient count from 7,607 in fiscal 2018 to 15,920 in fiscal 2019.

Direct clinic expenses for Q4 and full year 2019 were $615,814 and $826,276, respectively, compared to Q4 and full year 2018 direct clinic expenses of $115,655 and $417,047, respectively. This increase above prior year is attributable to the increase in number of patient visits.

Net loss from operations for Q4 and full year 2019 were $1,132,784 and $3,680,060, respectively, compared to Q4 and full year 2018 net loss of $592,899 and $4,309,373, respectively. This decrease below prior year is primarily attributable to the increase in net clinic revenues. While there was an increase in salaries and wages with the acquisition of Sun Valley, this increase was offset by a decline in share-based payments and legal and professional fees.

Net loss for Q4 and net loss for the full year 2019 were $1,942,084 and $4,301,663, respectively, compared to Q4 and full year 2018 net income of $1,342,930 and net loss of $3,789,918, respectively. This increase over prior year is primarily attributable to the recognition of goodwill and intangible asset impairment of $2,377,397 and $93,757, respectively. Partially offsetting these one-time expenses is an increase in the gain recognized on the warrant liability and conversion feature associated with the convertible debentures that resulted from the decrease in the Company’s share price and therefore the value of the warrants and convertible debentures exercisable.

During the year ended December 31, 2019, the Company used $2,273,188 in cash from operations after changes in non-cash working capital. The Company invested $3,828 towards property and equipment and raised $3,085,819 via proceeds from various issuances of shares, notes, and convertible debentures.

Please refer to the Company’s audited consolidated financial statements, related notes and accompanying Management Discussion and Analysis for a full review of the operations.

About Empower

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer

CONTACTS:

InvestorsDustin Klein Steven McAuley
 Director CEO
 647-620-5101 604-789-2146
 [email protected] [email protected]

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding the direction and growth prospects of the Company, the expansion of the company’s clinic and distribution network, the expected effect of the Vendors in their new roles with the Company, the effect on the lives of patients, the growth into a national brand, the effect of the Transaction, the diversification of the Company’s business model, the potential appeal to shareholders, the growth of the Company’s patient list and the effect thereof, the expected benefits for the company’s patient base and customers, the release of the cash consideration, the release of Shares being held in escrow in connection with the Transaction and statements regarding the Company’s proprietary product line “Sollievo”. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including that the Company may not be able to expand, that the Transaction may not have the expected results, and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

$KABN.ca Liquid Avatar to Join Apex Comics Group Presentation at Comic-Con @Home $MOS.ca $MOGO.ca $CTZ.ca $PTO.ca $PAY.ca

Posted by AGORACOM-JC at 4:15 PM on Thursday, July 23rd, 2020
This image has an empty alt attribute; its file name is image-3.png
  • Announced that on Saturday, July 25 at 5 pm Pacific / 8 pm Eastern, in conjunction with Apex Comics group CEO and Founder, Mariano Nicieza, KABN will be presenting a virtual discussion and overview of the Liquid Avatar platform (www.liquidavatar.com) at Comic-Con @ Home for comic book, fantasy, anime, manga and gaming fans worldwide
  • Event can be viewed at: https://comiccon2020.sched.com/event/d4zK/apex-comics-publishing-group-2020-2021-exclusive-previews
  • The Liquid Avatar platform allows for the management and control of digital identity as well as personal and private data and is available to consumers at no cost

TORONTO, CANADA / July 23, 2020 / KABN Systems NA Holdings Corp. (CSE:KABN) (the “Company” or “KABN” or “KABN North America“), a Canadian Fintech company that specializes in continuous online identity verification, management and monetization in Canada and the US, is pleased to announce that on Saturday, July 25 at 5 pm Pacific / 8 pm Eastern, in conjunction with Apex Comics group CEO and Founder, Mariano Nicieza, KABN will be presenting a virtual discussion and overview of the Liquid Avatar platform (www.liquidavatar.com) at Comic-Con @ Home for comic book, fantasy, anime, manga and gaming fans worldwide. The event can be viewed at: https://comiccon2020.sched.com/event/d4zK/apex-comics-publishing-group-2020-2021-exclusive-previews. The Liquid Avatar platform allows for the management and control of digital identity as well as personal and private data and is available to consumers at no cost.

This event also begins the launch of Liquid Avatar’s Open Call for the Artist community, allowing students, emerging artists, hobbyists and others to create and provide submissions for review, by a panel of experts, for feedback and potential inclusion into the Liquid Avatar Marketplace (“Marketplace”) coming later this summer. All approved Artists will have their own catalog presented in the Marketplace allowing them to showcase icons available for sale.

The Liquid Avatar Marketplace will offer users with a new type of Avatar experience in addition to their free icons that they can create in the platform’s Creative Studio. Liquid Avatar users will be able to acquire custom-designed and limited availability icons from leading pop culture, comic book, fantasy, manga, and contemporary Artists complete with an innovative digital authentication solution that has been traditionally managed as an on-site, personnel and location-based process. All Liquid Avatars acquired from the Marketplace will be supported with a unique Digital Certificate of Authenticity, allowing each custom icon to have its own Blockchain identifier that can be transferred from one user to another.

“The reaction from the professional Artist and Creator community has been outstanding and we’ve already received submissions of some great icons for the Liquid Avatar Marketplace,” said Mariano Nicieza, CEO and Founder Apex Comics Group. “By opening the program to the overall market and allowing other talented Artists to come forward and participate and create icons, I believe, will further enhance the opportunities for Liquid Avatar.”

Liquid Avatar has begun its North American launch program to early adopters and welcomes the public to request an invitation at: https://liquidavatar.com/liquid-avatar-early-adopter/

About KABN North America – www.kabnnaholdco.com

KABN Systems NA Holdings Corp. through its wholly owned subsidiary KABN Systems North America Inc. focuses on the verification, management and monetization of digital identity, empowering users to control and benefit from its use of their online identity. KABN propriety technology suite includes 4 key products:

KABN ID is an Always On, biometric and blockchain based digital identity validation and verification platform allowing users to continuously and confidently prove themselves throughout the online community.

Liquid Avatar allows users to create high quality digital icons representing their online personas. These icons, in conjunction with KABN ID, allows users to use Liquid Avatars to share public and permission based private data when they want and with whom they want. www.liquidavatar.com

KABN Card is a Visa approved prepaid card program allowing users to manage both digital and fiat currencies and earn cashback and other loyalty incentives. www.kabncard.com

KABN KASH is a cashback, loyalty and engagement program that powers the KABN revenue ecosystem.

KABN provides its products and services at no cost to consumers and generates revenues through permission-based partner programs. www.kabnkash.com

KABN Systems NA Holdings Corp. is publicly traded on the Canadian Securities Exchange under the symbol: KABN

For more information, please visit www.kabnnaholdco.com or www.kabnsystemsna.com

For further information, please contact:

Ben Kessler
Chief Executive Officer
647-725-7742 Ext. 700
[email protected]

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities under the KABN Financing in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but is not limited to, information concerning the ability of the Company to generate revenues, roll out new programs and to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.

TransCanna $TCAN.ca Seizes New Processing Opportunity and Expands Operations at Daly Street Building $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 4:15 PM on Wednesday, July 22nd, 2020
tcan-square
  • Announced that Lyfted Farms Inc. (a wholly-owned subsidiary) will build a processing division inside its Daly Street Building
  • Aas not originally planned in phase one in order to meet the increased demand for this service and ultimately increase profits margins
  • Once operational, the division will oversee the trimming, drying, curing, grading and packaging of cannabis, and support TransCanna’s strategy of vertical integration of the California cannabis market through distribution centers serving Northern California from the Daly Street building, and Southern California from the Company’s recently announced Lemoore facility

Vancouver, British Columbia–(July 22, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) TransCanna announces that Lyfted Farms Inc. (a wholly-owned subsidiary) will build a processing division inside its Daly Street Building that was not originally planned in phase one in order to meet the increased demand for this service and ultimately increase profits margins.

Once operational, the division will oversee the trimming, drying, curing, grading and packaging of cannabis, and support TransCanna’s strategy of vertical integration of the California cannabis market through distribution centers serving Northern California from the Daly Street building, and Southern California from the Company’s recently announced Lemoore facility.

“Once we received our final State License for the Daly Building, our already existing demand increased significantly. To meet this demand and seize the opportunity we saw to really drive our bottom line margin through processing, we sped up the timeline to add processing at this level,” said Bob Blink, TransCanna CEO. “We have the team and the space to execute this. Being agile enough to adapt to a changing market and identify opportunities for growth within it speaks to our collective mindset. When we run the numbers, we can see upon execution this service adding an additional 10% to our forecasted revenue targets,” adds Blink.

“This will facilitate the larger strategy of the Daly facility becoming a central distribution point for Lyfted Branded products and a wholesale processing center,” said Alan Applonie, company General Manager. “Converging marketing and buying interests into a single Northern California location gives state-wide buyers a broader range of products to purchase,” he adds.

The Processor License is an additional license type not included in the original statute specifically added for processors. As this is a new business segment whilst being built out, the Company has submitted an application for a Processor License and anticipates approximately a 90-day timeline to receive it.

The Daly building’s phase one deployment plan will also accommodate perpetual storage of at least 20,000 lbs. of cannabis flower in a climate-controlled atmosphere that will serve business-to-business cannabis market demand throughout California.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed, Company building cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors
Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation estimates and forecasts and statements as to management’s expectations for growth and the commencement of operations of the Company’s Daly facility.

The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including that operations will commence at the Company’s Daly facility in Modesto, California, as and when expected.

These forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially from any future results, events or developments expressed or implied by such forward-looking statements. Risks and uncertainties associated with the forward-looking information in this news release include, among others, dependence on obtaining and maintaining regulatory approvals, including state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete upgrades to its Daly facility in a timely manner; engaging in activities which currently are illegal under U.S. federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth;; reliance on management; and the effect of capital market conditions and other factors (including those related to the COVID-19 pandemic) on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look, except in accordance with applicable securities laws.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN